| 陈余思,白碧慧,胡 强,张榆铃,苏晓勇,高 丽.布地奈德混悬液联合沙丁胺醇雾化吸入治疗支气管哮喘的疗效及对炎症因子水平的影响[J].,2021,(13):2597-2600 |
| 布地奈德混悬液联合沙丁胺醇雾化吸入治疗支气管哮喘的疗效及对炎症因子水平的影响 |
| Efficacy of Nebulized Budesonide Suspension Combined with Salbutamol in the Treatment of Bronchial Asthma and the Influence on the Level of Inflammation Factors |
| 投稿时间：2020-10-28 修订日期：2020-11-24 |
| DOI：10.13241/j.cnki.pmb.2021.13.042 |
| 中文关键词: 布地奈德 沙丁胺醇 雾化吸入 支气管哮喘 炎症因子 疗效 |
| 英文关键词: Budesonide Salbutamol Aerosol inhalation Bronchial asthma Inflammation factor Efficacy |
| 基金项目:国家自然科学基金项目(81103541)；四川省卫生和计划生育委员会科研项目（16PL1073） |
|
| 摘要点击次数: 752 |
| 全文下载次数: 506 |
| 中文摘要: |
| 摘要 目的：探讨布地奈德混悬液联合沙丁胺醇雾化吸入治疗支气管哮喘的临床疗效及其对炎症因子水平的影响。方法：选择2018年6月至2019年6月我院收治的92例支气管哮喘患者随机分为对照组（n=46）和观察组（n=46），所有患者均给予常规基础治疗，对照组患者在常规治疗基础上给予雾化吸入沙丁胺醇治疗，观察组患者在对照组的基础上联合雾化吸入布地奈德混悬液治疗，疗程均为1周。比较两组患者的临床疗效及治疗前、后的血清炎症因子水平。结果：观察组患者临床总有效率为93.48%（43/46），明显高于对照组的78.26%（36/46）（P<0.05）。观察组患者哮喘、肺部的湿啰音和哮鸣音、咳嗽的消失时间均明显短于对照组（P<0.05）。治疗后两组患者血清中超敏C反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）、白细胞介素-1β（IL-1β）和白细胞介素-4（IL-4）水平较治疗前降低（P<0.05），且观察组低于对照组（P<0.05）。两组患者不良反应发生率分别为4.35%（2/46）、8.70%（4/46），二者相比差异无统计学意义（P>0.05）。结论：支气管哮喘采用雾化吸入布地奈德混悬液联合沙丁胺醇治疗可获得较好的临床疗效，改善支气管哮喘的临床症状的同时还可缓解患者的炎症反应，安全性较高，值得临床推广。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the efficacy of nebulized budesonide suspension combined with salbutamol in the treatment of bronchial asthma and the influence on the level of inflammation factors. Methods: 92 cases of bronchial asthma treated in our hospital from June 2018 to June 2019 were randomly divided into control group (n=46) and observation group (n=46), all patients were given routine basic treatment, the control group was treated with nebulized salbutamol on the basis of routine basic treatment, and the observation group was treated with nebulized budesonide suspension on the basis of the control group, the courses of treatment were one week. The clinical efficacy and the level of inflammatory factors before and after treatment were compared between the two groups. Results: The total effective rate of the control group was 93.48%(43/46), which was significantly lower than 78.26%(36/46) in the observation group (P<0.05). The asthma, pulmonary wet rales and wheeze, cough disappeared time of the observation group were significantly shorter than that of the control group(P<0.05). After treatment, the levels of serum high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-4 (IL-4) of the observation group were lower than that before treatment(P<0.05), and those in the observation group were lower than in the control group(P<0.05). The incidence of adverse reactions in two groups were 4.35%(2/46) and 8.70%(4/46) respectively, there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Nebulized budesonide suspension combined with salbutamol in the treatment of bronchial asthma can get better clinical efficacy, which can not only improve the clinical symptoms of bronchial asthma, but also alleviate the inflammatory reaction of patients with bronchial asthma, it has a high safety and worthy of clinical promotion. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
